165 related articles for article (PubMed ID: 21942250)
1. Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease.
Hughes AD; Jones LH
Future Med Chem; 2011 Oct; 3(13):1585-605. PubMed ID: 21942250
[TBL] [Abstract][Full Text] [Related]
2. Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review.
Ray NC; Alcaraz L
Expert Opin Ther Pat; 2009 Jan; 19(1):1-12. PubMed ID: 19441894
[TBL] [Abstract][Full Text] [Related]
3. Multivalent dual pharmacology muscarinic antagonist and β₂ agonist (MABA) molecules for the treatment of COPD.
Hughes AD; McNamara A; Steinfeld T
Prog Med Chem; 2012; 51():71-95. PubMed ID: 22520472
[No Abstract] [Full Text] [Related]
4. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
Cazzola M; Molimard M
Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
[TBL] [Abstract][Full Text] [Related]
5. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease.
Matera MG; Page CP; Cazzola M
Trends Pharmacol Sci; 2011 Aug; 32(8):495-506. PubMed ID: 21683458
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology and therapeutics of bronchodilators.
Cazzola M; Page CP; Calzetta L; Matera MG
Pharmacol Rev; 2012 Jul; 64(3):450-504. PubMed ID: 22611179
[TBL] [Abstract][Full Text] [Related]
7. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
Montuschi P; Ciabattoni G
J Med Chem; 2015 May; 58(10):4131-64. PubMed ID: 25587755
[TBL] [Abstract][Full Text] [Related]
8. Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease.
Busch-Petersen J; Lainé DI
Future Med Chem; 2011 Oct; 3(13):1623-34. PubMed ID: 21942252
[TBL] [Abstract][Full Text] [Related]
9. Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies.
Fitzgerald MF; Fox JC
Drug Discov Today; 2007 Jun; 12(11-12):472-8. PubMed ID: 17532532
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β
Rancati F; Linney ID; Rizzi A; Delcanale M; Knight CK; Schmidt W; Pastore F; Riccardi B; Mileo V; Carnini C; Cesari N; Blackaby WP; Patacchini R; Carzaniga L
Bioorg Med Chem Lett; 2021 Jun; 41():127975. PubMed ID: 33753262
[TBL] [Abstract][Full Text] [Related]
11. Considerations for new dual-acting bronchodilator treatments for chronic obstructive pulmonary disease.
de Miguel-Díez J; Jiménez-García R
Expert Opin Investig Drugs; 2014 Apr; 23(4):453-6. PubMed ID: 24392807
[TBL] [Abstract][Full Text] [Related]
12. Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules.
Hughes AD; Chin KH; Dunham SL; Jasper JR; King KE; Lee TW; Mammen M; Martin J; Steinfeld T
Bioorg Med Chem Lett; 2011 Mar; 21(5):1354-8. PubMed ID: 21310610
[TBL] [Abstract][Full Text] [Related]
13. Bronchodilators: current and future.
Cazzola M; Matera MG
Clin Chest Med; 2014 Mar; 35(1):191-201. PubMed ID: 24507846
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic therapy: novel approaches for chronic obstructive pulmonary disease.
Bailey WC; Tashkin DP
Proc Am Thorac Soc; 2007 Oct; 4(7):543-8. PubMed ID: 17878467
[TBL] [Abstract][Full Text] [Related]
15. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Mastrodicasa MA; Droege CA; Mulhall AM; Ernst NE; Panos RJ; Zafar MA
Expert Opin Investig Drugs; 2017 Feb; 26(2):161-174. PubMed ID: 28004591
[TBL] [Abstract][Full Text] [Related]
16. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
Beeh KM; Beier J
Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
[TBL] [Abstract][Full Text] [Related]
17. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
Ohar JA; Donohue JF
Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
[TBL] [Abstract][Full Text] [Related]
18. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.
Vogelmeier C; Banerji D
Ther Adv Respir Dis; 2011 Jun; 5(3):163-73. PubMed ID: 21511677
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological therapy of chronic obstructive pulmonary disease].
Montuschi P
Ann Ist Super Sanita; 2003; 39(4):557-72. PubMed ID: 15098576
[TBL] [Abstract][Full Text] [Related]
20. Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-β₂-agonist for the treatment of chronic obstructive pulmonary disease.
Osborne R; Clarke N; Glossop P; Kenyon A; Liu H; Patel S; Summerhill S; Jones LH
J Med Chem; 2011 Oct; 54(19):6998-7002. PubMed ID: 21863888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
